Navigation Links
Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
Date:4/7/2008

ively, are inferior to those of Enbrel-and efficacy, safety and tolerability are weighted more heavily by surveyed rheumatologists as key drivers of prescribing decisions," said Cindy Mundy, Ph.D., director at Decision Resources. "As a result, the improvements in dosing frequency that golimumab and Cimzia offer over Enbrel are not sufficient to propel either agent to the position of future gold standard."

About the Report

Rheumatoid Arthritis: Competitive, Crowded Market Sets the Bar High for Novel Agents is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com
'/>"/>

SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
2. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
3. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
4. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
5. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
6. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
7. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
8. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
9. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
10. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
11. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015 Discovery Laboratories, Inc. (Nasdaq: ... on developing aerosolized KL4 surfactant therapies for respiratory ... at 8:30 a.m. Eastern Time on Tuesday August 11, ... 2015 second quarter financial results along with providing ... press release announcing the second quarter 2015 financial ...
(Date:8/3/2015)... REDWOOD CITY, Calif., Aug. 3, 2015 AcelRx ... company focused on the development and commercialization of innovative ... a business update and reported financial results for the ... Business highlights include: , On July 23, ... (CHMP) adopted a positive opinion for Zalviso™ for the ...
(Date:8/3/2015)... FLINT, Mich., Aug. 3, 2015 Diplomat Pharmacy, Inc. ... announced financial results for the quarter ended June 30, 2015. ... June 30, 2014. Second Quarter 2015 Highlights ... of 49% or $266 million , Total prescriptions dispensed ... of 8.6% versus 5.5% , Adjusted EBITDA of $22.7 ...
Breaking Medicine Technology:Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18
... July 19, 2011 Spanish drug companies face a ... the United States.  From regulatory (FDA) and GMP compliance, ... there are many areas that must be coordinated.  Those ... company KIM and U.S. company VPCI have entered into ...
... July 19, 2011 Reportlinker.com announces that ... in its catalogue: The ... Discovery http://www.reportlinker.com/p0574968/The-Changing-Role-of-Natural-Products-in-Drug-Discovery.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development ... This report reveals how natural products have ...
Cached Medicine Technology:Spanish Drug Companies Have New Support Option for the U.S. Market 2The Changing Role of Natural Products in Drug Discovery 2The Changing Role of Natural Products in Drug Discovery 3The Changing Role of Natural Products in Drug Discovery 4
(Date:8/4/2015)... ... 04, 2015 , ... An article published July 27th by the ... method for encouraging people to lose weight. Specifically the study compared control patients with ... success, adding a financial incentive to the overall incentive of increased health. According to ...
(Date:8/4/2015)... ... August 04, 2015 , ... It’s hard to ... & Day Spa in Santa Barbara, CA is offering the solution by offering ... permanently eliminates sweat and odor glands in the underarms. This simple and permanent ...
(Date:8/4/2015)... ... 04, 2015 , ... Seedstock’s 4th Annual Sustainable Agriculture Conference, ... 2015, at UC San Diego, will explore innovations that farmers and entrepreneurs are ... resources efficiently against the dueling backdrop of a lingering Western drought and burgeoning ...
(Date:8/4/2015)... ... August 04, 2015 , ... Members receiving care from a ... – at a cost that is nine percent lower -- than those members at ... of New Jersey’s patient-centered programs. , “The promise of patient-centered, or value-based, care ...
(Date:8/4/2015)... ... August 04, 2015 , ... Increasingly, patients are ... calling a physician. In an effort to share more and better information with ... Pennsylvania to publicly share patient satisfaction ratings and comments about its doctors and ...
Breaking Medicine News(10 mins):Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 2Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 3Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3
... Hispanic youth report better dental health habits than their non-Hispanic ... researchers at Columbia University Mailman School of Public Health. ... the Journal of Health Care for the Poor and Underserved, ... community in America. , The study, a snapshot of more ...
... increase cancer growth, cause stroke and heart attacks, revised ... The U.S. Food and Drug Administration on Thursday approved ... which are drugs used to treat certain types of ... and Procrit, and detail their dangers to patients with ...
... Health, Inc.,(Nasdaq: VTIV ) today announced that ... at the 2007 Credit Suisse Healthcare Conference,taking place ... conference will,feature companies spanning all sectors of healthcare, ... presentation will take place on Tuesday, November 13 ...
... Nov. 8 Law Offices of Howard G. Smith,announces ... a lead plaintiff in,the securities class action lawsuit filed ... Micrus Endovascular Corporation ("Micrus" or,the "Company")(Nasdaq: MEND ) ... "Class Period"). The shareholder lawsuit is pending in,the United ...
... Monogram,Biosciences, Inc. (Nasdaq: MGRM ) announced today ... present a corporate overview at the,Lazard Fourth Annual Healthcare ... Time) at the New York Palace Hotel. To ... log on to http://www.monogrambio.com and go to ...
... injury, study finds , THURSDAY, Nov. 8 (HealthDay News) ... may cut their risk for fracture, Canadian researchers report. ... an increased risk of additional fractures, other health problems, ... osteoporosis patients are hip, spine, and wrist fractures. ...
Cached Medicine News:Health News:Study of minority New York City youth finds unequal burden of poor dental health 2Health News:FDA Issues New Warnings for Anemia Drugs 2Health News:FDA Issues New Warnings for Anemia Drugs 3Health News:inVentiv Health to Present at the 2007 Credit Suisse Healthcare Conference 2Health News:Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference 2Health News:Sticking With Meds Lowers Elderly Fracture Risk 2
... copolymer is an absorbable co-polymer synthesized ... and 18% glycolic acid. Unlike the ... 100% poly-L-lactic acid (PLLA) or 100% ... substantially amorphous (without crystallinity), meaning that ...
... POLYSORB™ Soft Tissue Anchor 3 mm is a ... to bone using sutures. The resorbable repair device ... bone, and is used to attach soft tissue. ... copolymer, derived from glycolide and lactide colored with ...
Umbrella Cancellous Harpoon...
... anchor is generally utilized when a surgeon would ... bone. Unlike other anchors that require the surgeon ... have that limitation. The only instrument required to ... The 4.4mm Stainless Steel Anchor is packaged sterile ...
Medicine Products: